The investigation centers on allegations that Aardvark Therapeutics provided materially untrue or misleading information in SEC disclosures tied to its IPO. Specifically, legal counsel is examining claims that the company overstated the commercial and regulatory prospects of ARD-101 while failing to disclose critical safety concerns that could impact the drug's market viability.
Kuehn Law Launches Investigation into Aardvark Therapeutics
Shareholders of Aardvark Therapeutics are under the microscope as Kuehn Law, PLLC, investigates potential breaches of fiduciary duty by the company’s leadership. The firm is scrutinizing whether directors misled investors regarding the safety of the firm's lead drug candidate, ARD-101, and the accuracy of its initial public offering filings.
Kuehn Law is urging investors who purchased AARD stock prior to March 1, 2025, to step forward. The firm, led by Justin Kuehn, operates on a contingency basis, covering all case costs for clients. Shareholders are encouraged to contact Sophia Anne Silayan to discuss potential legal recourse, as strict time limits may apply to enforcing individual rights in this derivative litigation.
Comments (0)
No comments yet. Be the first!